{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:34:47Z","timestamp":1793896487752,"version":"4.8.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03119-6","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:57:02Z","timestamp":1788163022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4483-5627","authenticated-orcid":false,"given":"Yu-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory M.","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Diebold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Coltoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan P.","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Zabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Foucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9156-7912","authenticated-orcid":false,"given":"Yasmin","family":"Abaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9889-2611","authenticated-orcid":false,"given":"Guru S.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Palmisiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9163-8792","authenticated-orcid":false,"given":"Adam S.","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-9289","authenticated-orcid":false,"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-1902","authenticated-orcid":false,"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-8160","authenticated-orcid":false,"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-4248","authenticated-orcid":false,"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed","family":"Kharfan-Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-3564","authenticated-orcid":false,"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"3119_CR1","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1002\/ajh.26546","volume":"97","author":"T Badar","year":"2022","unstructured":"Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, et al. Outcomes of TP53-mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97:E232\u2013e235.","journal-title":"Am J Hematol"},{"key":"3119_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01186-5","volume":"14","author":"M Shahzad","year":"2024","unstructured":"Shahzad M, Amin MK, Daver NG, Shah MV, Hiwase D, Arber DA, et al. What have we learned about TP53-mutated acute myeloid leukemia?. Blood Cancer J. 2024;14:202.","journal-title":"Blood Cancer J"},{"key":"3119_CR3","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2024024245","volume":"145","author":"DA Sallman","year":"2025","unstructured":"Sallman DA, Stahl M. TP53-mutated acute myeloid leukemia: how can we improve outcomes?. Blood. 2025;145:2828\u20132833.","journal-title":"Blood"},{"key":"3119_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193\u2013202.","journal-title":"Am J Hematol"},{"key":"3119_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01368-9","volume":"15","author":"O Jamy","year":"2025","unstructured":"Jamy O, El Kettani M, Shah K, Shallis RM, Diebold K, Coltoff A, et al. Outcomes of older patients with TP53-mutated myeloid neoplasms. Blood Cancer J. 2025;15:160.","journal-title":"Blood Cancer J"},{"key":"3119_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J. 2025;15:139.","journal-title":"Blood Cancer J"},{"key":"3119_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2025-6","volume":"146","author":"A Fathi","year":"2025","unstructured":"Fathi A, Perl A, Fell G, Jonas B, Ragon B, Mims A, et al. Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood. 2025;146:6\u20136.","journal-title":"Blood"},{"key":"3119_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood.2022015832","volume":"140","author":"AM Zeidan","year":"2022","unstructured":"Zeidan AM, Fenaux P, Gobbi M, Mayer J, Roboz GJ, Krauter J, et al. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood. 2022;140:285\u2013289.","journal-title":"Blood"},{"key":"3119_CR9","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA, Fronick CC, O\u2019Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016;375:2023\u201336.","journal-title":"N Engl J Med"},{"key":"3119_CR10","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","volume":"6","author":"NJ Short","year":"2019","unstructured":"Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019;6:e29\u2013e37.","journal-title":"Lancet Haematol"},{"key":"3119_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01290-0","volume":"15","author":"MV Shah","year":"2025","unstructured":"Shah MV, Hung K, Baranwal A, Wechalekar G, Al-Kali A, Toop CR, et al. Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 2025;15:88.","journal-title":"Blood Cancer J"},{"key":"3119_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"3119_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3119_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01479-x","volume":"16","author":"A Bazinet","year":"2026","unstructured":"Bazinet A, Bataller A, Chien K, Sasaki K, Montalban-Bravo G, Hammond D, et al. Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes. Blood Cancer J. 2026;16:48.","journal-title":"Blood Cancer J"},{"key":"3119_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1182\/bloodadvances.2023010417","volume":"8","author":"MT Nawas","year":"2024","unstructured":"Nawas MT, Kosuri S. Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS\/AML. Blood Adv. 2024;8:553\u201361.","journal-title":"Blood Adv"},{"key":"3119_CR16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood.2024027408","volume":"146","author":"JF Zeidner","year":"2025","unstructured":"Zeidner JF, Sallman DA, R\u00e9cher C, Daver NG, Leung AYH, Hiwase DK, et al. Magrolimab plus azacitidine vs physician\u2019s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study. Blood. 2025;146:590\u2013600.","journal-title":"Blood"},{"key":"3119_CR17","unstructured":"Aprea Therapeutics announces results of primary endpoint from phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). 28 December 2020. Available at: https:\/\/ir.aprea.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3. Accessed 18 August 2026."},{"key":"3119_CR18","doi-asserted-by":"publisher","first-page":"674","DOI":"10.18632\/oncotarget.28652","volume":"15","author":"T Badar","year":"2024","unstructured":"Badar T, Shahzad M, Atallah E, Litzow MR, Kharfan-Dabaja MA. Transplant or no transplant for TP53 mutated AML. Oncotarget. 2024;15:674\u20136.","journal-title":"Oncotarget"},{"key":"3119_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41375-023-01847-7","volume":"37","author":"T Badar","year":"2023","unstructured":"Badar T, Atallah E, Shallis R, Saliba AN, Patel A, Bewersdorf JP, et al. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023;37:799\u2013806.","journal-title":"Leukemia"},{"key":"3119_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"3119_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01000-2","volume":"14","author":"T Badar","year":"2024","unstructured":"Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, et al. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024;14:32.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03119-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03119-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03119-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:57:04Z","timestamp":1788163024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03119-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":21,"alternative-id":["3119"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03119-6","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TB: Received research funding from Amgen and Takeda, served in advisory board for Takeda, Amgen, Ascentage, Syndax, Geron, and Cogent Biosciences AP: Research Funding: Sumitomo, Pfizer, Incyte, Servier, Stemline. Honoraria: AbbVie, Amgen, Astellas, Cycle, Geron, Jazz, Novartis, Sobi, Syndax, Refined Oncology. Data Safety Monitoring Committee: Takeda. AC: Honoraria: Cogent, Sobi, PharmaEssentia, Speaking fees: Incyte, Blueprint Medicines. OJ: Advisory board participation for Ascentage, TERNS, Sellas. HM: Advisory Board\/Consultation for Geron, Ascentage, Abbvie, Syndax Therapeutics, Kite Gilead, Seres, Sobi, BMS, Incyte, Sanofi, Cartesian Therapeutics, AROG pharmaceuticals. Medical Monitor; NMDP, BMT CTN. NP: Consulting for Amgen, BMS, Foundation One, AstraZeneca, AbbVie.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}